Literature DB >> 10769724

Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy.

S Huber1, M Wagner, I Zuna, M Medl, H Czembirek, S Delorme.   

Abstract

BACKGROUND: We aimed to assess the mammographic features of locally advanced breast carcinoma treated with neoadjuvant chemotherapy and to evaluate morphological criteria that determine the value of mammography in therapy monitoring.
MATERIALS AND METHODS: We reviewed the pre- and post-therapeutic mammograms of 44 patients with stage III-breast carcinoma with regard to tumor characteristics and malignant calcifications and compared to histopathological results.
RESULTS: Delineation of the tumor proved to be the most significant criterion. In 34 tumors more than 50% of the lesion was defined; these showed a high correlation between the mammographically determined tumor diameter and that determined on histopathological examination (r = 0.77). Less than 50% of the mass was definable in 14 tumors; here the correlation between mammographically and histopathologically determined tumor diameter was low (r = -0.19).
CONCLUSIONS: The diagnostic value of mammography in the evaluation of tumor response to induction chemotherapy depends primarily on the extent to which the tumor can be delineated from the adjacent breast tissue. For tumors whose margins can be defined by more than 50% on the baseline mammogram, the diagnostic reliability of mammography is high. Ill-defined masses should preferably be assessed with other imaging procedures such as ultrasonography or magnetic resonance imaging.

Entities:  

Mesh:

Year:  2000        PMID: 10769724

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

1.  Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer.

Authors:  Filippo Montemurro; Laura Martincich; Giovanni De Rosa; Stefano Cirillo; Vincenzo Marra; Nicoletta Biglia; Marco Gatti; Piero Sismondi; Massimo Aglietta; Daniele Regge
Journal:  Eur Radiol       Date:  2005-01-27       Impact factor: 5.315

2.  Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer.

Authors:  Jason D Keune; Donna B Jeffe; Mario Schootman; Abigail Hoffman; William E Gillanders; Rebecca L Aft
Journal:  Am J Surg       Date:  2010-04       Impact factor: 2.565

3.  18F-FDG PET/CT for early prediction of response to neoadjuvant chemotherapy in breast cancer.

Authors:  Joan Duch; David Fuster; Montserrat Muñoz; Pedro Luís Fernández; Pilar Paredes; Montserrat Fontanillas; Flavia Guzmán; Sebastià Rubí; Francisco Juan Lomeña; Francesca Pons
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03-27       Impact factor: 9.236

Review 4.  Monitoring therapeutic efficacy in breast carcinomas.

Authors:  Anne A Tardivon; Liliane Ollivier; Carl El Khoury; Fabienne Thibault
Journal:  Eur Radiol       Date:  2006-05-30       Impact factor: 7.034

5.  Imaging in evaluation of response to neoadjuvant breast cancer treatment.

Authors:  L Ollivier; C Balu-Maestro; J Leclère
Journal:  Cancer Imaging       Date:  2005-05-24       Impact factor: 3.909

6.  Which imaging modality is superior for prediction of response to neoadjuvant chemotherapy in patients with triple negative breast cancer?

Authors:  Jordan J Atkins; Catherine M Appleton; Carla S Fisher; Feng Gao; Julie A Margenthaler
Journal:  J Oncol       Date:  2013-02-11       Impact factor: 4.375

7.  Can breast MRI help in the management of women with breast cancer treated by neoadjuvant chemotherapy?

Authors:  R M L Warren; L G Bobrow; H M Earl; P D Britton; D Gopalan; A D Purushotham; G C Wishart; J R Benson; W Hollingworth
Journal:  Br J Cancer       Date:  2004-04-05       Impact factor: 7.640

Review 8.  Assessment and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Comparison of Imaging Modalities and Future Perspectives.

Authors:  Valeria Romeo; Giuseppe Accardo; Teresa Perillo; Luca Basso; Nunzia Garbino; Emanuele Nicolai; Simone Maurea; Marco Salvatore
Journal:  Cancers (Basel)       Date:  2021-07-14       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.